总的来说，移民妇女的乳腺癌（BC）发病率比土生土长的妇女低，而BC死亡率较高。此外，移民妇女在国家BC筛查计划中参与率较低。为进一步研究这些方面，我们旨在确定荷兰鹿特丹土生土长和移民BC患者在发病率和肿瘤特征方面的差异。我们从荷兰癌症登记处中选择了2012年至2015年在鹿特丹诊断为BC的女性进行分析。按移民状态（即有或没有移民背景）计算发病率。通过多因素分析确定了调整后的奥斯比（OR）和95％置信区间（CI，区分筛查参与（是/否））。总共分析了1372例土生土长和450例移民BC患者。移民的BC发病率低于土生土长的妇女。总体而言，移民妇女在BC诊断时更年轻（53岁对64岁，p＜0.001），并且具有更高的阳性淋巴结风险（OR 1.76，95％CI 1.33-2.33）和高级别的肿瘤（OR 1.35，95％CI 1.04-1.75）。特别是未经筛查的移民妇女有更高的阳性淋巴结风险（OR 2.73，95％CI 1.43-5.21）。在接受筛查的妇女亚组中，我们观察到移民和土生土长患者之间没有显着差异。移民妇女的BC发病率低于土生土长妇女，但诊断通常在更年轻的年龄和不利的肿瘤特征下进行。参加筛查计划可以大大降低这种情况。因此，建议加强推广筛查计划的参与率。版权所有©2023年作者。Elsevier Ltd.保留所有权利。

In general, migrant women have a lower breast cancer (BC) incidence rate and higher BC mortality than autochthonous women. Further, migrant women show lower participation in the national BC screening program. To further investigate those aspects, we aimed to determine differences in incidence and tumor characteristics between autochthonous and migrant BC patients in Rotterdam, the Netherlands.We selected women diagnosed with BC in Rotterdam during 2012-2015 from the Netherlands Cancer Registry. Incidence rates were calculated by migrant status (i.e., women with or without migration background). Multivariable analyses revealed adjusted odds ratios (OR) and 95% confidence intervals (CI) on the association between migration status and patient and tumor characteristics, additionally stratified by screening attendance (yes/no).In total 1372 autochthonous and 450 migrant BC patients were included for analysis. BC incidence was lower among migrants than among autochthonous women. Overall, migrant women were younger at BC diagnosis (53 vs. 64 years, p < 0.001), and had higher risks of positive lymph nodes (OR 1.76, 95% CI 1.33-2.33) and high grade tumors (OR 1.35, 95% CI 1.04-1.75). Especially non-screened migrant women had higher risk of positive nodes (OR 2.73, 95% CI 1.43-5.21). Among the subgroup of screened women, we observed no significant differences between migrant and autochthonous patients.Migrant women have lower BC incidence than autochthonous women, but diagnosis was more often at younger age and with unfavorable tumor characteristics. Attending the screening program strongly reduces the latter. Therefore, promotion of participation in the screening program is recommended.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.